The big Alzheimer’s culprits are Amyloid and Tau. Biogen made Leqembi to treat amyloid. Now, they are betting on BIIB080 to treat tau. Learn how this exciting new treatment just got FDA Fast Track Designation.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
Why can vision loss come before memory loss in 10% of Alzheimer’s? A new study shows Posterior Cortical Atrophy (PCA), a type of Alzheimer’s, distributes proteins differently.
Participants in a new study had inherited genetic variants that lead to early-onset Alzheimer’s. Among those who received the drug the longest – an average of eight years – the treatment lowered the risk of developing symptoms from essentially 100% to about 50%.
Rosemary & sage extracts inspire a potential anti-inflammatory drug for Alzheimer’s. Scripps Research created a stable form of carnosic acid, improving memory in the lab.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
New research suggests antidepressants accelerate cognitive decline in dementia. Learn which drugs appear to be less harmful than others. Help your doctor make better treatment decisions.
(Video & Article) L.A.T.E. Dementia is frequently misdiagnosed as Alzheimer’s. That’s why, in January 2025, researchers created new guidelines. It affects millions of people, approximately 40% of people over 80. How is it recognized? What makes it different?
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.
A nutrient hidden in your daily meals could hold the key to preventing and slowing Alzheimer’s. Discover what Arizona researchers are revealing about the power of choline.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
